Hua Medicine (Shanghai) Ltd. (2552.HK) HKSE
3.65
-0.01(-0.27%)
Currency In HKD
- General
- Statistics
- Historical Data
- Profile
- Financials
3.65
-0.01(-0.27%)
Currency In HKD
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
168
First IPO Date
September 14, 2018
| Name | Title | Pay | Year Born |
| Li Chen | Founder, CEO & Executive Director | 10.79M | 1963 |
| Yi Zhang | Senior VP of Pharma Development, Chief Medical Officer China and Executive Director | 4.63M | 1976 |
| Chien Cheng Lin | Executive VP & Chief Strategy Officer | 6.05M | 1971 |
| Changhong Li | Chief Scientific Officer | 0 | 1969 |
| Fuxing Tang | Chief Technology Officer, Vice President of Chemical Manufacturing Control Department and Head of R&D in USA | 0 | 1967 |
| Chengde Wang | Head of IR | 0 | 1948 |
| Ying Xie | Vice President of Quality Assurance Division & Chief Quality Officer | 0 | N/A |
| Yu Lu | Vice President of Sales & Marketing | 0 | N/A |
| Wing Yan Yuen | Company Secretary | 0 | 1970 |
Hua Medicine (Shanghai) Ltd. operates as a clinical-stage drug development company that focuses on therapies for the treatment of diabetes in China. It develops Dorzagliatin or HMS5552, an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin that is in Phase I clinical trial for treatment of T2D. The company also offers Dorzagliatin in combination with Pioglitazone for NASH; in combination with GLP-1 for Alzheimer diseases; and in combination with late stage T2D and Type 1 Diabetes. In addition, it is developing mGLUR5 for the treatment of Parkinson's disease levodopa-induced dyskinesia. The company was incorporated in 2011 and is based in Beijing, China.